Tag Archives: ADCs

October, 2017

26 October
New Study: ‘Double Decker’ Antibody Technology Fights Cancer

JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy. The new …
Share

5 May
Seattle Genetics Terminates License Agreement with Immunomedics

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc. (Nasdaq: IMMU) for sacituzumab govitecan (IMMU-132) and settle the related litigation. The license agreement had not yet closed due to legal action brought by an …
Share

17 March
Scripps Florida Scientists Develop New Drug Delivery Method for Cancer Therapy

JUPITER, FL – March 16, 2017 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors. The study, led by TSRI Associate Professor Christoph …
Share

28 October
Igenica Partners with MedImmune to Research Anti-SAIL ADCs

BURLINGAME, Calif.–(BUSINESS WIRE)–Igenica Biotherapeutics, Inc., a company focused on the discovery and development of innovative antibody-based therapies for the treatment of cancer, announced today that it has entered into an oncology research agreement with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN). Igenica and MedImmune will …
Share